Pfizer (PFE) Liabilities and Shareholders Equity (2009 - 2026)

Pfizer (PFE) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $201.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 2.41% year-over-year to $201.1 billion in Q2 2026; TTM through Jun 2026 was $826.3 billion, a 2.44% decrease from a year earlier, with the FY2025 full-year figure at $208.2 billion, down 2.45% from the prior year.
• Liabilities and Shareholders Equity was $201.1 billion for Q2 2026 at Pfizer, down from $208.0 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $227.0 billion in Q4 2023 and troughed at $41.1 billion in Q3 2022.
• A 5-year average of $189.7 billion and a median of $208.0 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity sank 77.04% in 2022 and jumped 412.44% in 2024, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $197.2 billion in 2022, then climbed by 15.11% to $227.0 billion in 2023, then dropped by 5.99% to $213.4 billion in 2024, then fell by 2.45% to $208.2 billion in 2025, then retreated by 3.38% to $201.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $201.1 billion (Q2 2026), $208.0 billion (Q1 2026), and $208.2 billion (Q4 2025), per Business Quant data.